[S-1单药治疗经治晚期非小细胞肺癌患者]

[S-1 monotherapy in patients with pretreated advanced non-small cell lung cancer].

作者信息

Hashizume Toshihiko, Nakada Yusuke

机构信息

Dept. of Medicine, Yokohama Sakaekyosai Hospital, Japan.

出版信息

Gan To Kagaku Ryoho. 2009 Jun;36(6):963-7.

PMID:19542716

Abstract

BACKGROUND

The objective of this study was to evaluate the efficacy and toxicity of S-1 monotherapy in patients with pretreated advanced non-small cell lung cancer(NSCLC).

METHODS

We prospectively analyzed patients previously treated with a platinum-containing regimen or monotherapy with a third-generation chemotherapeutic drug. S-1 was orally administered at approximately 80 mg/m / 2day for 28 days followed by a 2-week rest period. We evaluated the efficacy and toxicities.

RESULTS

A total of 15 patients received S-1 monotherapy. Three partial responses were observed among them with an overall response rate of 20%. Toxicities of grade 3 or higher included anemia(13%), thrombocytopenia( 6%), fatigue(6%), anorexia(13%), diarrhea(13%), interstitialpneumonitis(6%)and infection(6%). The ratio of outpatient treatment period was 73.5%. The median time to progression, median survivaltime and 1-year survival rate were 4.2 months, 7.8 months and 27.8% respectively.

CONCLUSIONS

S-1 monotherapy was suggested to be effective and tolerable in patients with pretreated advanced NSCLC.

摘要

背景

本研究的目的是评估S-1单药治疗既往接受过治疗的晚期非小细胞肺癌（NSCLC）患者的疗效和毒性。

方法

我们前瞻性地分析了既往接受含铂方案或第三代化疗药物单药治疗的患者。S-1以约80mg/m²/天的剂量口服，持续28天，随后休息2周。我们评估了疗效和毒性。

结果

共有15例患者接受了S-1单药治疗。其中观察到3例部分缓解，总缓解率为20%。3级或更高等级的毒性包括贫血（13%）、血小板减少（6%）、疲劳（6%）、厌食（13%）、腹泻（13%）、间质性肺炎（6%）和感染（6%）。门诊治疗期的比例为73.5%。中位进展时间、中位生存期和1年生存率分别为4.2个月、7.8个月和27.8%。